文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌近距离放疗治愈的生化定义

A biochemical definition of cure after brachytherapy for prostate cancer.
PubMed 文献 · Radiother Oncol · 2020-04-27

基于7家机构14,220例局限期前列腺癌低剂量率近距离放疗患者数据,4年PSA≤0.2 ng/mL者10年无复发生存率98.7%(95%CI 98.3-99.0),15年96.1%(95%CI 94.8-97.2),三个独立验证队列确认10年FFR 97-99%,建议以此作为治愈的生化定义。

要点

  • 4年PSA≤0.2 ng/mL者10年FFR达98.7%,15年达96.1%。
  • PSA≤0.2组占可评估患者的77.1%,三个验证队列10年FFR为97-99%。
  • PSA分类与治疗成功强相关(p<0.0005),随PSA升高无病生存率下降。

核心结论

  • LDR前列腺近距离放疗后4年PSA≤0.2 ng/mL者10年以上无病生存率98.7%,建议作为治愈的生化定义。

研究设计与样本

  • 多中心回顾性分析7家机构14,220例局限期前列腺癌LDR近距离放疗患者,排除3.5年内临床失败者。
  • 4年(±6个月)无临床失败的8,746例患者PSA水平与10-15年疾病状态相关分析。

主要发现

  • 4年PSA≤0.2 ng/mL者占77.1%,10年FFR 98.7%(95%CI 98.3-99.0),15年FFR 96.1%(95%CI 94.8-97.2)。
  • 三个独立验证队列确认4年PSA≤0.2 ng/mL者10年FFR率为97-99%。
  • PSA分类(≤0.2、>0.2-≤0.5、>0.5-≤1.0、>1.0 ng/mL)与10年和15年无病生存率下降相关,与治疗成功强相关(p<0.0005)。

关键数值与推荐

  • 建议对LDR近距离放疗后随访≥4年且PSA≤0.2 ng/mL的患者采用治愈的生化定义。
  • 4年PSA≤0.2 ng/mL对应10年FFR 98.7%(95%CI 98.3-99.0)和15年FFR 96.1%(95%CI 94.8-97.2)。

临床怎么用

  • LDR前列腺近距离放疗后4年PSA≤0.2 ng/mL可作为治愈的生化判定指标,用于随访咨询和后续管理决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To identify a PSA threshold value at an intermediate follow-up time after low dose rate (LDR) prostate brachytherapy associated with cure, defined as long-term (10-15 year) freedom from prostate cancer. MATERIALS AND METHODS: Data from 7 institutions for 14,220 patients with localized prostate cancer treated with LDR brachytherapy, either alone (8552) or with external beam radiotherapy (n = 1175), androgen deprivation (n = 3165), or both (n = 1328), were analyzed. Risk distribution was 42.4% favorable, 49.2% intermediate, and 8.4% high-risk. Patients with clinical failure before 3.5 years were excluded. Kaplan-Meier analysis was used with clinical failure (local, distant, regional or biochemical triggering salvage) as an endpoint for each of four PSA categories: PSA ≤ 0.2, >0.2 to ≤0.5, >0.5 to ≤1.0, and >1.0 ng/mL. PSA levels at 4 years (±6 months) in 8746 patients without clinical failure were correlated with disease status at 10-15 years. RESULTS: For the 77.1% of patients with 4-year PSA ≤ 0.2, the freedom-from-recurrence (FFR) rates were 98.7% (95% CI 98.3-99.0) at 10 years and 96.1% (95% CI 94.8-97.2) at 15 years. Three independent validation cohorts confirmed 97-99% 10-year FFR rates with 4-year PSA ≤ 0.2. Successive PSA categories were associated with diminished disease-free rates at 10 and 15 years. PSA category was strongly associated with treatment success (p < 0.0005). CONCLUSIONS: Since 98.7% of patients with PSA ≤ 0.2 ng/mL at 4 years after LDR prostate brachytherapy were disease-free beyond 10 years, we suggest adopting this biochemical definition of cure for patients with ≥4 years' follow-up after LDR brachytherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Crook JM, Tang C, Thames H, et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020. PMID: 32442822. doi:10.1016/j.radonc.2020.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。